Shares of Ironwood (IRWD) are moving higher after its partner AbbVie (ABBV) reported Q3 Linzess sales of $315M, which beat Citizens JMP’s estimate of $241M. Analyst Jason Butler views the sales beat as a “clear positive” for Ironwood as it continues to evaluate strategic alternatives. Ironwood in late day trading is up 24%, or 36c to $1.86.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRWD: